In support of the notion that LGR6 is oncogenic, LGR6 shRNA-mediated knockdown in ovarian cancer cells is reported to attenuate stemness by inhibiting the Wnt/β-catenin pathway, and in vivo experiments have shown LGR6 knockdown sensitizes the SK-OV-3 ovarian cancer xenograft model to chemotherapy (cisplatin) [112]. This evidence concerns the gene LGR6 and ovarian carcinoma.